325 related articles for article (PubMed ID: 2953870)
41. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
42. Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; List A; Rutland M; Knox BS
Prostate; 1988; 12(2):119-27. PubMed ID: 2966931
[TBL] [Abstract][Full Text] [Related]
43. Results obtained in the treatment of prostate cancer patients with Zoladex.
Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
[No Abstract] [Full Text] [Related]
44. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
[TBL] [Abstract][Full Text] [Related]
45. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
[TBL] [Abstract][Full Text] [Related]
46. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex.
Holdaway IM; Parr CE; France J
Aust N Z J Obstet Gynaecol; 1991 May; 31(2):164-5. PubMed ID: 1834050
[TBL] [Abstract][Full Text] [Related]
47. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
Furr BJ
Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
[TBL] [Abstract][Full Text] [Related]
48. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
49. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
50. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
51. Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist.
Ward JA; Furr BJ; Valcaccia B; Curry B; Bardin CW; Gunsalus GL; Morris ID
J Androl; 1989; 10(6):478-86. PubMed ID: 2533593
[TBL] [Abstract][Full Text] [Related]
52. The first clinical use of depot buserelin for advanced prostatic carcinoma.
Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
[TBL] [Abstract][Full Text] [Related]
53. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
[TBL] [Abstract][Full Text] [Related]
54. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival.
Emtage LA; Perren TJ; Stuart NS; Arkell DG; Wallace DM; Hughes MA; Cottam J; Farrar D; Young CH; Blackledge GR
Br J Urol; 1987 Nov; 60(5):436-42. PubMed ID: 2962689
[TBL] [Abstract][Full Text] [Related]
56. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Ryan PG; Peeling WB
Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
[TBL] [Abstract][Full Text] [Related]
57. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Lunglmayr G
Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
[No Abstract] [Full Text] [Related]
58. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
59. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
60. Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis.
Mettler L; Steinmüller H; Schachner-Wünschmann E
Hum Reprod; 1991 May; 6(5):694-8. PubMed ID: 1834693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
